Financial Analysis: Anika Therapeutics (ANIK) & Biogen (BIIB)
Anika Therapeutics (NASDAQ: ANIK) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Earnings and Valuation
This table compares Anika Therapeutics and Biogen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$103.38 million||7.61||$32.54 million||$2.13||25.19|
|Biogen||$11.45 billion||6.08||$3.70 billion||$16.31||20.17|
Biogen has higher revenue and earnings than Anika Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
85.0% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 88.3% of Biogen shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings for Anika Therapeutics and Biogen, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Anika Therapeutics currently has a consensus target price of $57.00, suggesting a potential upside of 6.22%. Biogen has a consensus target price of $345.54, suggesting a potential upside of 5.05%. Given Anika Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Anika Therapeutics is more favorable than Biogen.
Volatility and Risk
Anika Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
This table compares Anika Therapeutics and Biogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Biogen beats Anika Therapeutics on 9 of the 15 factors compared between the two stocks.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Biogen Company Profile
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.